This article considers how the longstanding debate about patent law and biotechnology is playing out in the emerging field of synthetic biology. Synthetic biology draws on molecular biotechnology, chemical engineering, genomics, and information technology to create new tools and techniques with the potential to yield transformative applications in energy, medicine, and many other areas. There has been concern that very broad patents in synthetic biology could impede the development of innovative products and public access to them, thwarting the policy goals of the patent system. Some synthetic biologists are seeking patents, while others are sharing their work in order to avoid the pitfalls of the patent system. The article investigates whether synthetic biology raises new intellectual property issues, and whether law reform or new policies are required. It analyzes the likely impact of key United States case law, such as the Myriad decision on the patentability of synthetic biology technologies. The article argues that the major processes and tools in synthetic biology are likely to meet the legal tests for patentable subject matter. It then presents a detailed case study of the examination practices of the United States Patent and Trademark Office in relation to patent families filed by scientists at the J. Craig Venter Institute. The case study shows the patent system to be working well to narrow the scope of broad claims and avoid granting patents for technology too early in its development. The article further argues that there are significant differences between synthetic biology and earlier controversial subject matter, such as human genes and genetic tests. It concludes that while synthetic biology patents do pose possible risks to the goals of the patent system, they are likely to be less problematic in this regard than patents on earlier genetic technologies.
INTRODUCTION
S ynthetic biology ''aims to apply standardized engineering techniques to biology and thereby create organisms or biological systems with novel or specialized functions to address countless needs. '' 1 Synthetic biologist Bonnie Bassler explains that: ''[S]ynthetic biologists promise to take the foundational knowledge acquired by traditional biologists and, using principles from engineering, refine, excel and apply it at scales that could achieve unprecedented good for the public. We now have the hope of efficiently applying biological solutions to some of the grandest problems facing the world.'' Synthetic biology combines several existing scientific disciplines, including molecular biotechnology, chemical engineering, genomics (the study of whole genomes), and information technology.
During the short history of synthetic biology, there have been two moral panics in response to announcements of scientific developments in the field. Both announcements related to research of the J. Craig Venter Institute (the Venter Institute). The successful identification of a minimal set of genes required for a particular bacterium to survive in a laboratory, ''the minimal bacterial genome,'' was announced by the Venter Institute in 2006.
3 The corresponding patent application, and a related application for ''synthetic genomes,'' resulted in a minor panic about how these patents would impact upon scientific research. 4 The second panic occurred following the 2010 announcement that a ''self-replicating synthetic bacterial cell'' had been created at the Venter Institute. This was publicized very prominently and was followed by an explosion of media coverage, triggering a wave of policy discussion in the United States and around the world. 5 President Barack Obama asked his Presidential Commission for the Study of Bioethical Issues (the Commission) to investigate ''the implications of this scientific milestone, as well as other advances that may lie ahead in this field of research. '' 6 It was directed to consider ''the potential medical, environmental, security, and other benefits of this field of research,'' in addition to considering its risks. 7 In synthetic biology, Venter's Synthetic Genomics Inc. and other commercial entities are pursuing patent rights. Following the synthetic cell announcement, Venter claimed that ''this is clearly the first life form totally developed out of a computer and by humans, so it is much closer to a human invention. '' 8 This pursuit of patent protection is in sharp contrast to the open, sharing approach of the BioBricks community, a community of researchers within the field. 9 These researchers are proactively sharing research and information online. In particular, they are sharing information about standard biological parts, a building block in synthetic biology research. A ''standard biological part'' is a sequence of DNA with wellcharacterized properties that acts as a functional unit. 10 Commentators have queried how synthetic biology will interact with the patent system. 11 The anti-technology ETC Group has strongly opposed some synthetic biology patent applications, arguing that they could create monopolies on fundamental technology in synthetic biology. 12 This article considers patenting in synthetic biology with a view to answering the question of whether novel legal issues arise as compared to previous biotechnologies, and whether law reform or new policies are required to manage synthetic biology patents. One of the key roles of regulation in relation to emerging technologies is to promote desirable innovation. 13 The goal of the regulatory intervention represented by the patent system is to incentivize innovation. In theory, the grant of monopoly property rights in an invention provides a reward for the inventive effort and capital that has been expended, in turn creating an incentive to innovate.
14 If the patent system instead operates so as to hinder research and innovation, as has been argued in some areas of the life sciences, this would be a problematic unintended consequence of the regulatory intervention. 15 Therefore, this article assesses whether the patent system is likely to operate in such an unintended, inhibitory fashion in relation to synthetic biology research.
One of the major objections raised to patents in the life sciences is that these do not fall within the scope of patentable subject matter. Hence, this article examines the application of case law on patentable subject matter in Bilski et al. v. Kappos The likely patentability of various tools and techniques is considered in order to illuminate the potential impact of patents on synthetic biology research. I argue that the key processes underpinning synthetic biology will meet the tests for patentable subject matter under the recent case law. The patentability of synthetic DNA constructs and standard biological parts is more complex, but these tools, too, are likely to meet the tests set out in these cases. There is also potential for patents on genetic sequences to impact upon synthetic biology research, and the patentability of these is discussed. I argue that it is important for the development of synthetic biology that standard biological parts should be accessible. This access to basic tools will promote research and development in the field.
The article then presents a case study of the examination practices of the United States Patent and Trademark Office (USPTO) in relation to patent families filed by scientists at the Venter Institute. This section analyzes whether the patent system is operating to deal adequately with applications in synthetic biology, or whether new criteria or policy tools need to be considered. I argue that the case study shows that the patent system is working to narrow down the scope of broad claims and avoid granting patents for technology too early in its development.
POLICY DEBATES OVER PATENTING IN THE LIFE SCIENCES
Patent law in the United States has been controversial in its application to life sciences. Various commentators have expressed concern about the potential impact of patenting in biotechnology and biomedical research, and this debate is ongoing. The patenting of tools and applications has caused a furor in relation to gene patents, pharmaceutical drugs, genetically modified crops, and embryonic stem cell research. 17 The debates have centered on issues of access to research tools and research areas, access to and costs of health care, and ownership of living things. There have been debates about whether the technological neutrality of the patent system can be maintained in light of emerging biotechnologies, and whether sui generis rules are required.
There are two major concerns about patenting in the life sciences which run through this debate. Some of these controversies have centered on the interpretation and application of the criteria for a valid patent, such as the debate over whether genes should constitute patentable subject matter. Other controversies have centered on how patent holders use their rights-for example, the granting of exclusive licenses. Some patent holders have engaged in licensing or enforcement behavior that has earned them the nickname ''patent trolls.'' A patent troll is an inventor (or patent holder) who is not using 13 See or commercializing their invention. 18 In particular, it refers to a patent holder who is not intending to use the invention, but has acquired the patent in order to hold those wishing to use it to ransom by charging high fees. 19 In addition, there has been concern that changes in innovation policy in the United States have altered academic scientific culture so that there are now greater commercial incentives associated with university research, meaning that scientists have become less likely to share their research with each other.
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A. Broad patents on foundational technologies
In literature regarding the impact of patents on biomedical research, it has been argued that patents can become problematic if they are broad and granted over foundational or enabling technologies and tools, which would be needed in a wide range of projects for future innovation and development in a field. 21 Such patents could create a situation in which one entity could control or direct scientific progress in that field, possibly limiting progress.
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There is also evidence from a number of different fields of technology showing the hindering impact of very broad, foundational patents.
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In some cases, it is argued that such a broad patent over a foundational tool or technology should not have been granted because it does not fall within the scope of patentable subject matter.
24 Under x 101 of the United States Patent Act, ''[W]hoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. '' 25 While x 101 is interpreted broadly, products of nature, laws of nature, physical phenomena, and abstract ideas are not patentable. 26 The reasons for limiting the scope of patentable subject matter were discussed in the U.S. Supreme Court's decision in Mayo Collaborative Services Inc. v. Prometheus Inc., in which Justice Breyer held that: ''[P]henomena of nature . mental processes, and abstract intellectual concepts are not patentable, as they are the basic tools of scientific and technological work.'' 27 He pointed out that monopolization of such basic tools could impede rather than promote innovation. 28 Further, the ''basic underlying concern'' that ''patent law not inhibit further discovery by improperly tying up the future use of laws of nature'' had been repeatedly stated by the Supreme Court. 29 This danger was seen as particularly acute where the claim was merely an ''instruction to 'apply the natural law,' or otherwise foreclosed more future invention than the underlying discovery could reasonably justify.'' 30 It was seen as important to compare the potential for the patent to limit future innovation with the inventor's contribution to innovation.
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It has been argued for more than a decade that patents on human genetic sequences are foundational patents which are likely to have a damaging impact on genetics research, though there is debate about their actual impact. In the Myriad litigation, it was argued that sequences of human DNA fall within the judicial exclusion of products of nature and therefore are not patentable subject matter.
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The Association for Molecular Pathology and other plaintiffs had brought a challenge against various patents held by Myriad Genetics Inc. (Myriad) relating to the breast and ovarian cancer genes BRCA1 and BRCA2. The presence of certain mutations in these genes increases a woman's average chance of developing breast and ovarian cancers. Id. at 1301. 29 Id.
30
Id.
31
Id. at 1303. Myriad held patents relating to these genes and methods of genetic testing. It had issued cease and desist letters to other providers of genetic tests and became the sole provider in the United States. The plaintiffs claimed that Myriad's patents on isolated sequences of DNA, stretches of ''complementary DNA'' (cDNA), and methods of comparing and analyzing genetic sequences were invalid. 34 The plaintiffs claimed that these patents impeded research and data sharing in the scientific field. 35 Further, they claimed that the patents compromised patient care, and hindered improvements to testing methods for these cancers. Patients could not seek a second test result to confirm that provided by Myriad. The stakes in this litigation were thus very high for patients, researchers, and the biotechnology industry.
Arguments about the problematic nature of broad patents have also been made on the basis that such patents are sometimes granted where the scope of the claims is overly broad, and not adequately supported by the disclosure of information in the patent specification. For example, in the Myriad litigation in the Federal Circuit, Judge Bryson discussed patent breadth in his partial dissent. He considered the scope of the claims and the actual contribution of the inventor relative to the claims and their impact. 36 He noted that ''substantial adverse effects on research and treatment'' were likely to occur if the claims were upheld. 37 The claims for short stretches of DNA and cDNA were framed so broadly that they covered sequences found in BRCA genes as well as in many other genes. Judge Bryson held that Myriad had not contributed to the understanding of other genes. Such broad claims could impede innovation in genetics.
For these reasons, rigorous examination of patent applications by the USPTO to make sure they meet these tests is important to avoid impeding innovation. The USPTO's examination of patents in synthetic biology is considered in the case study in this article.
B. Patent thickets and the anticommons
In terms of patent impact, Heller and Eisenberg warned of a potential ''tragedy of the anticommons'' in which ''[a] proliferation of intellectual property rights upstream may be stifling life-saving innovations further downstream in the course of research and product development. '' 38 In this theory, an anticommons may develop where there is fragmentation of proprietary rights in a field, so that there are too many patents of narrow scope. 39 This can make it costly to negotiate all the licenses needed to obtain freedom to operate in a particular area, and there is potential for a particular patent holder to ''hold up'' those who wish to operate in a field where access to that patent is needed. 40 A ''crowded'' patent environment like this is often described as a ''patent thicket.'' 41 The anticommons argument has been raised as a concern in relation to patents on DNA sequences, as there are many patented sequences within the human genome. 42 However, there is also scholarship criticizing the theory of anticommons development in biomedical research and suggesting that it is not borne out by empirical research. For example, studies in various jurisdictions have shown that while there are many patents on genetic sequences, anticommons problems are not often observed. 43 Some studies have shown that genetics researchers use strategies such as inventing around a patent or willfully ignoring patents and infringing them. impact of biotechnology patents and access to patented biotechnology.
SYNTHETIC BIOLOGY PATENT ENVIRONMENT
A. Patent environment
In the United States, patent applications for synthetic biology have fallen into two broad categories: 1) biological tools, methods, and products; and 2) computer programs. 45 The computer program category includes software for design of biological devices and genetic circuits, 46 use in DNA assembly, 47 design of synthetic nucleic acids, 48 and analysis of biochemical activity within cells. 49 This article focuses on the biological category. In that category, some patent applications have focused on the construction of a synthetic cell. Scientists at the Venter Institute have filed applications for patents on technology including a minimal bacterial genome, DNA assembly, methods for cloning and manipulating genomes, methods of installing a genome into a cell, and methods for producing a synthetic cell. 50 There are also patents for methods of DNA synthesis. 51 Other patent applications in the United States have involved the creation of useful biological products from cells, such as Jay D. Keasling and colleagues' production of artemisinic acid-an anti-malarial drug precursor-in a genetically modified cell.
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The spin-off company, Amyris, now has a granted patent for production of isoprenoids through biosynthetic pathways using engineered bacteria, including artemisinic acid. 53 This same platform technology is being used in biofuels development.
There are now many patents for biofuels. For example, Synthetic Genomics has patents on methylbutanol and dimethyloctane as advanced biofuels. 54 Synthetic Genomics also has a patent for ''Production of Branched-Chain Alcohols by Photosynthetic Microorganisms.'' 55 Amyris has patents on jet fuel and methods for making it, as well as molecules and fuel compositions of various kinds and methods for making them. restrictive licensing and smotheringly broad patent interpretations could make a shambles of synthetic biology.'' 57 Intellectual property experts James Boyle and Arti K. Rai have raised concern about the potential for both broad foundational patents and patent thickets to impede innovation in synthetic biology. 58 In her evidence to the Commission, Rai argued that there should not be an attempt to eliminate patenting in synthetic biology, as patents provide important incentives. 59 However, she highlighted two important policy areas to consider: quality of patents and licensing behavior of patent holders. 60 A ''high quality'' patent is one that properly meets the statutory requirements for patentability. 61 Because synthetic biology is actually comprised of several approaches to biological engineering, several different patent problems could theoretically arise. Broad patents are a potential concern in synthetic biology. 62 At this early stage of synthetic biology's development, there is potential for broad patents over foundational technologies and processes of synthetic biology to cause problems for innovation in the field. Broad patents on foundational technologies could result in fewer end products being developed in synthetic biology. This could occur if, for example, a broad patent was granted over the minimal genome developed at the Venter Institute. This patent application had the potential to cover a foundational technology. 63 Potentially, a patent thicket could arise if many patents are granted on the basic building blocks used in synthetic biology: standard biological parts. Potential synthetic biology products have been likened to complex technologies which contain many components, such as those in electronics and information technology. 64 An analogy can be drawn with electrical circuits, as synthetic biologists are attempting to build ''genetic circuits'' comprised of units of DNA. 65 Also, a human-designed synthetic cell would be a complex entity which might make use of a number of components that could be subject to patent protection themselves. 66 This complex nature means that it is unlikely one company would hold all the intellectual property rights necessary for a particular research project in synthetic biology. 67 Negotiating many licenses could become costly and there is high potential for unintentional patent infringement. 68 This complexity has led some commentators to stress that the introduction and fostering of openness and sharing in synthetic biology is critical.
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Patents on genetic sequences also have the potential to impact upon research in synthetic biology. Many standard biological parts have been placed in the public domain and are being shared by synthetic biologists via the Registry of Standard Biological Parts (the Registry). However, Rai gave evidence to the Commission's inquiry that there were many patents on genetic sequences. 70 Thus, parts in the Registry could potentially touch on many existing patents. 71 Patent thickets could therefore become problematic in synthetic biology, similar to problems which occurred in the information technology industry. 72 Thus, the recent case law regarding patentability of DNA sequences is an important issue for synthetic biology research and is analyzed below. 70 Rai, supra note 59. 71 Id.
SYNTHETIC BIOLOGY AND PATENTABLE SUBJECT MATTER
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Biotechnology Law Report Volume 36, Number 2related-approaches to the engineering of biology. These approaches are the ''construction approach'' (attempting to build human-made genomes and cells, as well as minimal genomes); the ''parts agenda'' (creating ''standard biological parts'' from DNA, which can be combined to create biological devices); and ''metabolic engineering,'' such as changing whole genetic pathways in microorganisms to produce useful products. These approaches are underpinned by common enabling technology in DNA synthesis, DNA assembly, and software for designing DNA.
Therefore, applying patent case law to synthetic biology is more complex than in some preceding areas of technology, such as genetic testing or embryonic stem cell research. There are multiple types of technology under discussion in the synthetic biology field. Thus, this section breaks these down into synthetic biology processes, synthetic DNA, and standard biological parts. The patentability of DNA sequences is also important in the synthetic biology context.
A. Processes
The patentability of processes has been discussed in the decisions of Bilski, Mayo, Alice, and Myriad. In Bilski, the Supreme Court had to decide whether the claims were for a patentable process or just an abstract idea. The disputed patent was for a method of hedging against risk when buying and selling commodities in the energy market. The claims included a method and a reduction of this to a formula. There were also claims to the use of this formula in the energy market.
In the decision below, the Court of Appeals had held that the test to determine ''whether a process claim is tailored narrowly enough to encompass only a particular application of a fundamental principle rather than pre-empt the principle itself'' is whether ''(1) it is tied to a particular machine or apparatus, or (2) it transforms a particular article into a different state or thing. '' 73 On appeal, the Supreme Court held that this ''machine or transformation test'' was a ''useful and important clue, an investigative tool,'' but ''is not the sole test for deciding whether an invention is a patent-eligible process. '' 74 Further, under Gottschalk v. Benson, ''transformation and reduction of an article 'to a different state or thing' '' is a clue where the claimed method does not involve a machine. 75 This decision was subsequently applied in the decisions in Mayo and Myriad.
In Mayo, the disputed patents (licensed to Prometheus) were for methods of using the concentration of certain metabolites of a drug in the blood of patients to determine whether the dosage should be adjusted. 76 The metabolism of the drug in the body was known to vary between patients. The level of metabolites was an indicator of whether the drug dosage was too low, and the drug could be ineffective, or too high, causing harmful effects. The patents claimed a method of optimizing drug dosage using these correlations.
Justice Breyer delivered the Supreme Court's opinion. He held that precedents require that ''a process that focuses upon the use of a natural law [must] also contain other elements or a combination of elements, sometimes referred to as an 'inventive concept,' sufficient to ensure that the patent in practice amounts to significantly more than a patent upon the natural law itself.'' 77 An application of a law of nature may be patentable, and so the question is ''do the patent claims add enough to their statements of the correlations [i.e., the laws of nature] to allow the processes they describe to qualify as patent-eligible processes that apply natural laws? '' 78 Merely adding some ''well understood, routine, conventional activity'' to the process would not generally be sufficient to meet the test. 79 Further, just limiting an idea to one field of use was not sufficient to make it patentable.
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In relation to the disputed patents in Mayo, Justice Breyer held that the additional step of ''administering'' the drug merely indicated the audience of the invention (doctors administering this class of drug) and the step of ''determining'' the metabolite levels comprised ''well understood, routine, conventional activity'' which did not significantly add to the process. 81 Together, the claims amounted to telling doctors to ''apply the law,'' and such patents had been held to be invalid in the past. 82 Thus, the claims did not sufficiently add to the law of nature to make the claimed process patent eligible. Id. at 1294. 78 Id. at 1297-1299. 79 Id. at 1298. 80 Id. at 1301. 81 Id. at 1298. 82 Id. at 1299-1301. 83 Id. at 1299-1302.
genetic recombination within a cell, would have to add ''enough'' to those natural processes that they could be described as applying the processes.
In 2014, the Supreme Court affirmed and applied the decision in Mayo in Alice. The patent claims in that case concerned a ''computer implemented scheme for mitigating 'settlement risk' (i.e., the risk that only one party to a financial transaction will pay what it owes) by using a third-party intermediary.'' 84 The Court viewed the decision in Mayo as laying out a two-step test for ''distinguishing patents that claim laws of nature, natural phenomena and abstract ideas from those that claim patent-eligible applications of those concepts.'' 85 First, the Court considers whether the claims encompass one of these patent-ineligible concepts. If they do, then the Court considers what has been added to the patentineligible concept, and whether this is sufficient to transform it into an eligible application. 86 In Alice, the Court found that the claims were directed to an abstract idea. Similar to the ''risk hedging'' claimed in Bilski, the use of ''intermediated settlement'' was a longstanding economic practice. This could not be transformed into a patent-eligible application by adding the use of a ''generic computer'' to implement the abstract idea. The claims for a method, a computer system, and a computer-readable medium all failed for these reasons.
In Myriad, the plaintiffs claimed that Myriad's patents on methods of comparing DNA sequences were invalid as they claimed the abstract idea of comparing gene sequences and preempted a natural phenomenon, the correlation between certain genetic mutations and predisposition to cancer. 87 In the Federal Circuit, Judge Lourie, with whom Judges Bryson and Moore concurred on this issue, found that the claims were invalid as they claimed an abstract mental process. They could not be made valid by limiting the claim to breast cancer genes or certain mutations.
The plaintiffs also claimed that Myriad's patents for a method of establishing the effectiveness of potential cancer drugs were not eligible for patent protection. 88 Judge Lourie held that the method of screening potential cancer drugs was patent eligible under the machine or transformation test. The steps of growing cells and determining growth rate were transformative. Further, the claim was not so abstract as to claim a scientific principle; it was tied to a type of cell, a type of therapeutic compound, and a specific method of determining growth rate. Thus, where methods involve steps which use or create novel, ''transformed'' subject matter, this indicates that the method is patent eligible.
In 2012, the Supreme Court ordered the Court of Appeal for the Federal Circuit to reconsider its Myriad decision in light of the Supreme Court's decision in Mayo. The Court of Appeals came to the same result as above, for essentially the same reasons. 89 Applying Mayo, Judge Lourie held that the claims for a method of screening drugs included steps of growing ''transformed,'' man-made cells with altered BRCA genes in the presence and absence of the drugs. These transformed cells had ''enhanced function and utility.'' 90 The process was patent eligible: ''performing operations, even known types of steps, on, or to create, novel, i.e., transformed subject matter is the stuff of which most process or method invention consists.'' 91 Further, the claims were restricted to certain cell types transformed with certain genes, and the impact on growth of a specific drug type was to be tested.
Methods such as generating a synthetic genome by assembling smaller pieces of DNA or standard components, or producing a synthetic cell by installing such a synthetic genome, are likely to be patentable subject matter under these tests. While they utilize natural processes, such as genetic recombination, within a cell, those processes of nature are only part of the methods claimed. These methods go beyond the processes of nature to transform existing matter into something which does not exist in nature. There are various additional steps, such as treating DNA and cells with different enzymes, and designing DNA sequences that can be joined together. These methods also go beyond adding routine, conventional, well-understood activity to a process of nature because they transform the existing matter into a new product with different utility. These methods are thus distinguishable from the law of nature claimed in Mayo, where nothing was added other than the instruction to apply the law. They are more analogous to the transformed cells which were found to be patentable subject 
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Biotechnology Law Report Volume 36, Number 2matter in Myriad. Thus, the processes would meet the tests in Mayo and Myriad (Federal Circuit).
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Synthetic biology processes are also likely to meet the machine or transformation test, because they would have transformative steps. For example, a method such as installing a genome into a cell involves steps such as preparing an isolated genome or synthesizing a genome, preparing a recipient cell, and installing the genome. 93 These would transform ''a particular article into a different state or thing'' as required in Bilski and Gottschalkthe resulting cell with a new genome inside. Similarly, while DNA assembly processes utilize the natural action of cells and enzymes, they are transformative because a new nucleic acid molecule is generated.
It is important to note that if there were claims for synthetic biology processes which did involve natural phenomena, the cases show that these could not become patent eligible merely by adding the use of a computer to perform or implement the process. Computer software for designing DNA cassettes for assembly or other processes would need to add something more to the natural phenomena than ''applying it'' on a computer.
Patent-eligible processes in synthetic biology would also have to meet the other criteria for patent validity. Some of the basic processes for which patents have been sought by the Venter Institute, discussed in the second part of this article, have been rejected under other criteria for patent validity, such as obviousness, lack of novelty, lack of enablement, and failure to provide a sufficient written description.
B. Genetic sequences
Patentability of DNA is an important issue in the context of BioBricks and other standard biological parts, because it affects the question of whether such parts could infringe existing genetic sequence patents. 94 In Myriad, the plaintiffs objected to both the patents on isolated sequences of DNA and stretches of cDNA. cDNA is made in the laboratory for particular experimental purposes. Within the genomes of natural organisms, there are stretches of the genetic code that do not contain coding information for protein production. cDNA ''contains the same proteincoding information found in a segment of natural DNA but omits portions within the DNA segment that do not code for proteins. '' 95 In 2010, Judge Sweet of the District Court, Southern District of New York, decided that both the isolated DNA sequences and cDNA sequences were not patentable subject matter. 96 The Court of Appeals for the Federal Circuit reversed these findings. 97 Judge Lourie, writing for the majority, noted that for compositions of matter, the relevant test is drawn from Diamond v. Chakrabarty (Chakrabarty): ''whether human intervention has given 'markedly different' or 'distinctive'' characteristics' from what is found in nature.'' 98 All three judges agreed that the cDNA molecules were patentable, as they have a different structure and genetic sequence from DNA found in nature.
The Supreme Court gave its decision in 2013. The petitioners had asked the Supreme Court to decide the question: ''[A]re human genes patentable?'' 99 Myriad maintained that the isolated DNA had a different structure from the natural genomic DNA. The United States government as amicus curiae argued that isolated DNA should not be patentable. However, cDNA should be considered patent eligible, because it is ''an artificial creation in the laboratory.'' Also, patents on cDNA would not stop the use of the original gene by others for medical or scientific research.
Justice Thomas held that ''a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, but that 92 In Myriad, the decision on Myriad's process patents was not appealed to the Supreme Court, thus the Supreme Court only decided an appeal on the composition of matter patents. 93 cDNA is patent eligible because it is not naturally occurring.'' 100 He concurred with the discussion in Mayo of the policy behind exceptions to patentability under x 101. He reiterated that courts have long held that x 101 contains important implicit exceptions: '''[L]aws of nature, natural phenomena, and abstract ideas are not patentable.' Rather, 'they are the basic tools of scientific and technological work' that lie beyond the domain of patent protection.'' 101 Without this exception, patents could ''tie up'' the use of those basic tools and inhibit innovation. This would be ''at odds with the very point of patents, which exist to promote creation.'' 102 Again referring to Mayo, he held that ''patent protection is a delicate balance between creating 'incentives that lead to creation, invention and discovery' and 'imped[ing] the flow of information that might permit, indeed spur invention.''' 103 Justice Thomas held that Myriad's ''principal contribution was uncovering the precise location and sequence'' of the breast cancer genes. Distinguishing this case from Chakrabarty, he held that ''Myriad did not create anything . it found an important and useful gene, but separating that gene from its surrounding genetic material is not an act of invention. Groundbreaking, innovative, or even brilliant discovery does not by itself satisfy the x 101 inquiry.'' 104 Although the location of the genes was previously unknown and required extensive research to uncover, ''extensive effort alone is insufficient to satisfy the demands of x 101.'' 105 Justice Thomas rejected the argument that the severing of chemical bonds to isolate the DNA created a non-naturally occurring molecule. The patents relied on the genetic information encoded in the genes, not the chemical structure of the molecule. Unlike the Court of Appeals, the Supreme Court was not deferential to the existing USPTO practice. Justice Thomas held that Congress had not specifically endorsed the USPTO's practice in legislation.
By contrast, it was held that ''cDNA does not present the same obstacles to patentability as naturally occurring, isolated DNA segments'' because it is a molecule that is not naturally occurring: ''the lab technician unquestionably creates something new when cDNA is made. cDNA retains the naturally occurring exons of DNA, but it is distinct from the DNA from which it was derived. As a result, cDNA is not a 'product of nature' and is patent eligible under x 101.'' 106 Thus, the Supreme Court in Myriad has altered the approach to patentability of isolated DNA molecules with naturally occurring sequences, and held these to be beyond the scope of patentable subject matter. Prior to the Supreme Court's decision in Myriad, use of standard biological parts might have infringed patents where the sequence of a part encompassed a sequence that is within a patented stretch of DNA. 107 Thus, under the Court of Appeal's decisions in Myriad and the existing USPTO practice, users of standard biological parts could have been infringing patents. This potential access problem had been noted in the synthetic biology context. 108 However, the new approach to isolated DNA under the Supreme Court's decision in Myriad means that although standard biological parts may cover sequences of patented DNA, those patents can no longer be enforced. The infringement potential has now been negated under this decision. Therefore, a thicket of DNA patents is unlikely to hinder synthetic biology research.
C. Synthetic DNA
The patentability of synthetic DNA is important because in the future, DNA synthesis is likely to increasingly become the method used for producing human-designed DNA constructs such as standard biological parts. The costs of DNA synthesis are decreasing and the efficiency is improving. 109 In analyzing the likely patentability of synthetic DNA and standard biological parts, it is necessary to consider how much they differ from naturally occurring DNA. DNA is a unique type of molecule which has a physical structure and form, but also carries encoded information in the genetic sequence of the DNA. There is an important distinction between the physical instantiation (the tangible form) of a stretch of DNA and its informational origin. The physical instantiation refers to how the actual physical DNA has been created. For example, it could have been created by using the polymerase chain reaction to copy an existing piece of natural DNA. More recently, it could have been synthesized Currently, many parts are constructed from sequences which have their informational origin in natural organisms. For example, the Registry of Standard Biological parts contains promoters from a number of microorganisms. Under the Supreme Court decision in Myriad, standard biological parts are unlikely to be patentable where they just reproduce a naturally occurring sequence. However, parts are often engineered to have minor changes from the natural sequence. For example, to use the BioBricks Assembly Protocol, small changes would have to be made to the naturally occurring genetic sequence. 130 Under Myriad, this may be enough to make them patent eligible. Standard biological parts have utility in construction of biological devices, so they are likely to meet the requirement for enlarged utility over naturally occurring DNA. Thus, they are analogous to the cDNA which was found to be patentable subject matter in Myriad.
In addition, composite parts or biological devices are being produced which combine several basic parts together to produce a biological device which can conduct a function within a cell. While the genetic sequences of the basic parts might be derived from naturally occurring sequences, the combination of these sequences could result in a stretch of DNA which is not identical to any naturally occurring genetic sequence. This takes synthetic biology even further from naturally occurring phenomena, and it is unlikely that such a device would be regarded as a product of nature.
Due to the strong culture of openness and sharing in the synthetic biology community, it is unlikely that many within that community would seek patents on parts or devices. However, the field of synthetic biology encompasses bio-entrepreneurs and commercially funded ventures, as well as research scientists working within an academic setting and a culture of sharing. Therefore, it is possible that parts will be patented. It is certainly possible that a patent troll could disrupt research in synthetic biology, including within the standard biological parts community, if it withheld access to a patented element needed for this research or sought to use reach-through licenses to control the commercialization of that research.
Thus, it is important that open sharing arrangements have been created under which scientists can volunteer to contribute these parts to a ''commons'' and share them with other researchers. 131 This has been going on for a number of years and thousands of parts are already in the public domain.
Access to standard biological parts is also important due to synthetic biology's emphasis on standardization. Synthetic biology's parts agenda was founded by leading synthetic biologist Drew Endy and collaborators to address the fact that biological engineering was ''still an expensive, unreliable and ad hoc research process.'' 132 Endy and colleagues blamed biology's lack of standards for biological function and other measures for costs and inefficiencies. 133 Thus, they saw a need for ''the development of technologies and promulgation of standards that support the definition, description and characterization of the basic biological parts, as well as standard conditions that support the use of parts in combination. '' 134 In the parts agenda, standardization is achieved through the development, definition, and distribution of standard biological parts themselves, and through the development of technical standards for use in parts research. The technical standards being developed relate to matters such as defining and describing parts, assembling them in the laboratory, and measuring the activity of molecules encoded by parts. 135 Standardization efforts can be seen to distinguish synthetic biology from other life sciences research. 136 Specific patent problems could arise from this standardization. 137 For example, if standard parts or devices are patented, there is the potential for issues to arise if these parts or devices are then used in standard tools or techniques in synthetic biology. Problems can occur when a standard becomes widely used in a field, but incorporates patented elements. 138 The patent holder could withhold access to the patent needed to use the standard, which is problematic if the standard is already widely used. 139 This is particularly problematic if it is difficult to subsequently change the standard. 140 
